Averly Health has launched as a joint venture between Pharmacy2U and Reset Health, combining clinical assessment, prescribing, pharmacy fulfilment and ongoing patient management within a single cardiometabolic care service.
The new business is targeting obesity, type 2 diabetes and cardiovascular disease. Reset Health is contributing specialist cardiometabolic clinical services and digital technology, while Pharmacy2U is providing digital prescribing, dispensing and nationwide pharmacy infrastructure.
Averly says the services and infrastructure brought together by its two parents already support more than two million patients each month. That figure relates to the existing operations underpinning the venture rather than an established Averly patient base. The new company has assembled a dedicated team from both organisations alongside additional hires.
The launch comes as the NHS expands weight-management treatment while trying to manage the clinical and operational demands created by a large eligible population. NHS England is phasing access to tirzepatide for obesity in primary care, with an initial cohort of around 220,000 patients due to gain access over the first three years of a 12-year rollout.
That programme is not limited to supplying medication. NHS guidance requires wraparound care when tirzepatide is prescribed for obesity through primary care, including clinical follow-up and behavioural support. Commissioners therefore need pathways that can connect assessment, prescribing and continuing care rather than treating each stage as a separate transaction.
Averly’s structure is designed around a similar operating problem. Bringing clinical management and pharmacy fulfilment under one organisation could reduce the number of hand-offs between providers where commissioners choose to procure an integrated service. It also creates a common structure for follow-up and outcomes monitoring.
The launch announcement does not disclose the financial terms or ownership split of the joint venture, nor does it identify a new NHS contract awarded directly to Averly. Its immediate scale therefore comes from the capabilities of Pharmacy2U and Reset Health rather than a disclosed commissioning pipeline of its own.
That distinction will become more important as the market develops. NHS England’s obesity programme is being widened in stages partly to protect primary-care capacity and give commissioners time to establish workable delivery models. Integrated care boards can use centrally funded wraparound services or make local arrangements that meet the required clinical and behavioural-support standards.
Providers seeking a larger role in those pathways will have to demonstrate more than dispensing capacity. Clinical governance, prescribing oversight, medicine supply, behavioural support and outcome measurement all form part of a service that may continue over an extended period.
The overlap between obesity, type 2 diabetes and cardiovascular disease also gives the venture a broader field than weight-management medication alone. NHS prioritisation for obesity treatment already takes account of conditions including hypertension, dyslipidaemia, sleep apnoea, type 2 diabetes and cardiovascular disease when assessing clinical need.
Averly enters that market with established pharmacy and clinical infrastructure behind it. Its progress will be determined by the contracts it secures and the outcomes it can demonstrate once services are delivered under the joint venture itself, rather than by the scale of its parent businesses alone.
You must be logged in to post a comment.